{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open-Label+Placebo&page=13",
    "query": {
      "intervention": "Open-Label Placebo",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 1998,
    "total_pages": 200,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open-Label+Placebo&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open-Label+Placebo&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T23:41:18.219Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01738451",
      "title": "A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "GSK2118436 75 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2013-01-22",
      "completion_date": "2014-11-28",
      "has_results": false,
      "last_update_posted_date": "2017-11-13",
      "last_synced_at": "2026-10-19T23:41:18.219Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Memphis, Tennessee • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01738451"
    },
    {
      "nct_id": "NCT00139776",
      "title": "Study Of \"Continuous Use\" Of Celecoxib Vs. \"Usual or Intermittent Use\"",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Osteoarthritis, Knee",
        "Osteoarthritis, Hip"
      ],
      "interventions": [
        {
          "name": "Celecoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 875,
      "start_date": "2005-07",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2021-03-29",
      "last_synced_at": "2026-10-19T23:41:18.219Z",
      "location_count": 67,
      "location_summary": "Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 58 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00139776"
    },
    {
      "nct_id": "NCT01664624",
      "title": "Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Roflumilast",
          "type": "DRUG"
        },
        {
          "name": "Alogliptin",
          "type": "DRUG"
        },
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo to roflumilast",
          "type": "DRUG"
        },
        {
          "name": "Placebo to alogliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2012-07",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2017-02-01",
      "last_synced_at": "2026-10-19T23:41:18.219Z",
      "location_count": 2,
      "location_summary": "Chula Vista, California • Orlando, Florida",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01664624"
    },
    {
      "nct_id": "NCT05199090",
      "title": "Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "MBL949",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 126,
      "start_date": "2022-02-10",
      "completion_date": "2023-05-11",
      "has_results": true,
      "last_update_posted_date": "2024-10-09",
      "last_synced_at": "2026-10-19T23:41:18.219Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Morehead City, North Carolina • Knoxville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Morehead City",
          "state": "North Carolina"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05199090"
    },
    {
      "nct_id": "NCT05999240",
      "title": "Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-10-01",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-19T23:41:18.219Z",
      "location_count": 2,
      "location_summary": "Lawrence, Kansas • White Plains, New York",
      "locations": [
        {
          "city": "Lawrence",
          "state": "Kansas"
        },
        {
          "city": "White Plains",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05999240"
    },
    {
      "nct_id": "NCT03267680",
      "title": "IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Squamous Cell Carcinoma In Situ",
        "Vulvar High Grade Squamous Intraepithelial Lesion"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Indomethacin",
          "type": "DRUG"
        },
        {
          "name": "IRX-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Multivitamin",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER",
        "DIETARY_SUPPLEMENT",
        "PROCEDURE"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "25 Years and older · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2017-11-08",
      "completion_date": "2024-03-13",
      "has_results": true,
      "last_update_posted_date": "2025-04-13",
      "last_synced_at": "2026-10-19T23:41:18.219Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03267680"
    },
    {
      "nct_id": "NCT05171855",
      "title": "A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Adult Growth Hormone Deficiency",
        "Endocrine System Diseases",
        "Hormone Deficiency"
      ],
      "interventions": [
        {
          "name": "Lonapegsomatropin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ascendis Pharma Endocrinology Division A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "23 Years",
        "maximum_age": "81 Years",
        "sex": "ALL",
        "summary": "23 Years to 81 Years"
      },
      "enrollment_count": 220,
      "start_date": "2021-12-16",
      "completion_date": "2024-12-23",
      "has_results": true,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-10-19T23:41:18.219Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Torrance, California • Chicago, Illinois + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05171855"
    },
    {
      "nct_id": "NCT02051608",
      "title": "A Study of Gantenerumab in Participants With Mild Alzheimer Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Gantenerumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 389,
      "start_date": "2014-03-27",
      "completion_date": "2021-04-16",
      "has_results": true,
      "last_update_posted_date": "2023-02-10",
      "last_synced_at": "2026-10-19T23:41:18.219Z",
      "location_count": 30,
      "location_summary": "Sun City, Arizona • Tucson, Arizona • Costa Mesa, California + 27 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02051608"
    },
    {
      "nct_id": "NCT02018536",
      "title": "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "GSK2336805 30 mg",
          "type": "DRUG"
        },
        {
          "name": "GSK2336805 60 mg",
          "type": "DRUG"
        },
        {
          "name": "GSK2336805 120 mg",
          "type": "DRUG"
        },
        {
          "name": "TMC435 150 mg (Treatment A)",
          "type": "DRUG"
        },
        {
          "name": "GSK2336805 60 mg (Treatment B and part of Treatment C and D)",
          "type": "DRUG"
        },
        {
          "name": "TMC435 100 mg (part of Treatment C)",
          "type": "DRUG"
        },
        {
          "name": "TMC435 150 mg (part of treatment D)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen R&D Ireland",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "20 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2013-10",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2014-06-17",
      "last_synced_at": "2026-10-19T23:41:18.219Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02018536"
    },
    {
      "nct_id": "NCT04153149",
      "title": "HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Transthyretin Amyloidosis (ATTR) With Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "Vutrisiran",
          "type": "DRUG"
        },
        {
          "name": "Sterile Normal Saline (0.9% NaCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 655,
      "start_date": "2019-11-26",
      "completion_date": "2026-12-02",
      "has_results": true,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-10-19T23:41:18.219Z",
      "location_count": 17,
      "location_summary": "La Mesa, California • Los Angeles, California • Stanford, California + 13 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04153149"
    }
  ]
}